<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02174536</url>
  </required_header>
  <id_info>
    <org_study_id>DSCHC002</org_study_id>
    <nct_id>NCT02174536</nct_id>
  </id_info>
  <brief_title>A Double Blind Randomized Study Using Placenta Derived Decidual Stromal Cells for Hemorrhagic Cystitis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska Institutet</source>
  <brief_summary>
    <textblock>
      A prospective double blind randomized study comparing placenta derived decidual stromal cells
      with placebo for hemorrhagic cystitis after allogeneic hematopoietic cell transplantation. It
      is hypothesized that the decidual stromal cell therapy will be superior to placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with grade 2-4 hemorrhagic cystitis will be randomized to receive either decidual
      stromal cell therapy at approximately 1x106 cells/kg or placebo on two occasions at weekly
      intervals. Patients not responsive within 2 weeks will receive decidual stromal cells at
      approximately 1x106 cells/kg openly.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Days to disappearence of macroscopic hematuria or clots</measure>
    <time_frame>1 month after inclusion</time_frame>
    <description>Each day, patients fill out a form were they state whether they have macroscopic hematuria or not.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to disappearance of pain or urges</measure>
    <time_frame>1 month after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to disappearance of microscopic hematuria</measure>
    <time_frame>1 month after inclusion</time_frame>
    <description>Each day patients, with the help of a urinary test stick, fill out a form were they state whether they have microscopic hematuria or not.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transplant related mortality</measure>
    <time_frame>1 year after inclusion</time_frame>
    <description>All mortality except relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of severe infections</measure>
    <time_frame>1 year after inclusion</time_frame>
    <description>Incidence of severe bacterial, viral or fungal infections.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of graft versus host disease</measure>
    <time_frame>One year after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall actuarial survival</measure>
    <time_frame>Actuarial</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hemorrhagic Cystitis</condition>
  <condition>Stem Cell Transplantation</condition>
  <condition>Decidual Stromal Cells</condition>
  <arm_group>
    <arm_group_label>Decidual Stromal cell therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Decidual stromal cell therapy (approximately 1x10^6 cells/kg) for hemorrhagic cystitis in addition to Misoprostol therapy (0,2mg, 3 times/day) on two occasions at weekly intervals.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Receives placebo (masked i.v. infusion, same amount as an infusion of decidual stromal cells) in addition to Misoprostol therapy (0,2mg, 3 times/day).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Decidual stromal cells</intervention_name>
    <description>Decidual stromal cells (approximately 1x10^6 cells/kg) will be infused intravenously.</description>
    <arm_group_label>Decidual Stromal cell therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hemorrhagic cystitis grade 2-4

          -  Receives Misoprostol therapy

        Exclusion Criteria:

          -  Patients with urinary urge without macroscopic hematuria or clots
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olle Ringdén, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olle Ringdén, MD, PhD</last_name>
    <phone>+46858582672</phone>
    <email>olle.ringden@ki.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Helen Kaipe, PhD</last_name>
    <phone>+46700901052</phone>
    <email>helen.kaipe@ki.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Karolinska Institutet</name>
      <address>
        <city>Stockholm</city>
        <zip>14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olle Ringdén, MD, PhD</last_name>
      <phone>+46858582672</phone>
      <email>olle.ringden@ki.se</email>
    </contact>
    <investigator>
      <last_name>Olle Ringdén, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2014</study_first_submitted>
  <study_first_submitted_qc>June 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2014</study_first_posted>
  <last_update_submitted>June 24, 2014</last_update_submitted>
  <last_update_submitted_qc>June 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Olle Ringdén</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

